Stryker Co. (NYSE:SYK) is First Western Trust Bank’s Largest Position

First Western Trust Bank trimmed its stake in Stryker Co. (NYSE:SYK) by 0.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,495,906 shares of the medical technology company’s stock after selling 1,232 shares during the quarter. Stryker makes up 58.1% of First Western Trust Bank’s holdings, making the stock its biggest position. First Western Trust Bank owned approximately 0.92% of Stryker worth $1,258,701,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of SYK. Prudential PLC grew its holdings in Stryker by 1.6% during the fourth quarter. Prudential PLC now owns 6,732 shares of the medical technology company’s stock valued at $2,424,000 after purchasing an additional 104 shares during the period. Landscape Capital Management L.L.C. bought a new position in shares of Stryker during the 4th quarter worth $328,000. Annis Gardner Whiting Capital Advisors LLC increased its holdings in Stryker by 3.1% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 2,736 shares of the medical technology company’s stock worth $987,000 after acquiring an additional 83 shares during the last quarter. Arete Wealth Advisors LLC raised its stake in Stryker by 11.0% in the 4th quarter. Arete Wealth Advisors LLC now owns 1,204 shares of the medical technology company’s stock valued at $433,000 after acquiring an additional 119 shares during the period. Finally, World Investment Advisors lifted its holdings in Stryker by 30.1% during the fourth quarter. World Investment Advisors now owns 10,593 shares of the medical technology company’s stock valued at $3,814,000 after purchasing an additional 2,451 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Price Performance

SYK opened at $368.12 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company has a market cap of $140.51 billion, a price-to-earnings ratio of 47.44, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The stock has a fifty day simple moving average of $382.64 and a two-hundred day simple moving average of $374.41. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the company posted $3.46 earnings per share. Research analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Insider Buying and Selling at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. JMP Securities restated a “market perform” rating on shares of Stryker in a research note on Tuesday, February 18th. Needham & Company LLC restated a “buy” rating and set a $442.00 target price on shares of Stryker in a research report on Friday, March 21st. Barclays lifted their price target on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Royal Bank of Canada increased their price target on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Finally, Argus set a $450.00 price target on shares of Stryker in a research report on Monday, February 3rd. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $421.90.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.